T J Gal1, Jon A Slezak2, Alexandra E Kejner2, Quan Chen3, Bin Huang4. 1. University of Kentucky, Department of Otolaryngology-Head and Neck Surgery, Lexington, KY, United States. Electronic address: tjgal2@uky.edu. 2. University of Kentucky, Department of Otolaryngology-Head and Neck Surgery, Lexington, KY, United States. 3. University of Kentucky, Markey Cancer Center, Lexington, KY, United States. 4. University of Kentucky, Markey Cancer Center, Lexington, KY, United States; University of Kentucky, Department of Biostatistics, Lexington, KY, United States.
Abstract
OBJECTIVE: To characterize temporal trends in treatment patterns for oropharyngeal carcinoma, and to evaluate the emerging role of surgical therapy in the era of transoral robotic surgery (TORS). METHODS: Patients with oropharynx cancer between 2004 and 2016 identified using the National Cancer Database. Demographics and primary treatment modalities were obtained. Treatment was classified as surgery alone, surgery with radiation/chemotherapy, or primary radiation/chemotherapy. Annual distribution of cases treated by the various modalities was tabulated by site and early (I/II) versus late (III/IV) stage disease (AJCC 7th edition). The "TORS era" was defined as beginning in 2010. RESULTS: 149,534 patients were identified. The majority (56.8%) were treated with radiation ± chemotherapy. 53,069 patients had surgery as part of treatment, 72.6% (N = 38,533) of which received adjuvant therapy. 5293 TORS procedures were performed between 2010 and 2016 with trends away from open and other endoscopic procedures. Despite a 31.0% increase in the number of cases treated surgically from before TORS (2009) to 2016, the percentage of cases treated surgically decreased from 35.0% to 32.7%, with a 44.2% increase in non-surgical therapy. Increases in the percentage of patients treated surgically were observed for base of tongue tumors (24.3-25.2%) and early stage disease (59.9-62.2%). CONCLUSION: Despite the increase in the overall number of patients with oropharynx cancer, the percentages of patients treated surgically remains relatively stable. Notable increases were observed for base of tongue tumors and early stage disease.
OBJECTIVE: To characterize temporal trends in treatment patterns for oropharyngeal carcinoma, and to evaluate the emerging role of surgical therapy in the era of transoral robotic surgery (TORS). METHODS: Patients with oropharynx cancer between 2004 and 2016 identified using the National Cancer Database. Demographics and primary treatment modalities were obtained. Treatment was classified as surgery alone, surgery with radiation/chemotherapy, or primary radiation/chemotherapy. Annual distribution of cases treated by the various modalities was tabulated by site and early (I/II) versus late (III/IV) stage disease (AJCC 7th edition). The "TORS era" was defined as beginning in 2010. RESULTS: 149,534 patients were identified. The majority (56.8%) were treated with radiation ± chemotherapy. 53,069 patients had surgery as part of treatment, 72.6% (N = 38,533) of which received adjuvant therapy. 5293 TORS procedures were performed between 2010 and 2016 with trends away from open and other endoscopic procedures. Despite a 31.0% increase in the number of cases treated surgically from before TORS (2009) to 2016, the percentage of cases treated surgically decreased from 35.0% to 32.7%, with a 44.2% increase in non-surgical therapy. Increases in the percentage of patients treated surgically were observed for base of tongue tumors (24.3-25.2%) and early stage disease (59.9-62.2%). CONCLUSION: Despite the increase in the overall number of patients with oropharynx cancer, the percentages of patients treated surgically remains relatively stable. Notable increases were observed for base of tongue tumors and early stage disease.
Authors: Kevin Fung; Teresa H Lyden; Julia Lee; Susan G Urba; Frank Worden; Avraham Eisbruch; Christina Tsien; Carol R Bradford; Douglas B Chepeha; Norman D Hogikyan; Mark E P Prince; Theodoros N Teknos; Gregory T Wolf Journal: Int J Radiat Oncol Biol Phys Date: 2005-08-08 Impact factor: 7.038
Authors: S S Kao; J Micklem; E Ofo; S Edwards; D Dhatrak; A Foreman; S Krishnan; J-C Hodge Journal: J Laryngol Otol Date: 2017-05-08 Impact factor: 1.469
Authors: Robert Haddad; Anne O'Neill; Guilherme Rabinowits; Roy Tishler; Fadlo Khuri; Douglas Adkins; Joseph Clark; Nicholas Sarlis; Jochen Lorch; Jonathan J Beitler; Sewanti Limaye; Sarah Riley; Marshall Posner Journal: Lancet Oncol Date: 2013-02-13 Impact factor: 41.316
Authors: David J Sher; Mary Jo Fidler; Roy B Tishler; Kerstin Stenson; Samer al-Khudari Journal: Int J Radiat Oncol Biol Phys Date: 2015-11-10 Impact factor: 7.038
Authors: Lisette van der Molen; Maya A van Rossum; Lori M Burkhead; Ludi E Smeele; Frans J M Hilgers Journal: Eur Arch Otorhinolaryngol Date: 2008-09-30 Impact factor: 2.503
Authors: Jennifer R Cracchiolo; Shrujal S Baxi; Luc G Morris; Ian Ganly; Snehal G Patel; Marc A Cohen; Benjamin R Roman Journal: Cancer Date: 2016-03-11 Impact factor: 6.860
Authors: James T Parsons; William M Mendenhall; Scott P Stringer; Robert J Amdur; Russell W Hinerman; Douglas B Villaret; Giselle J Moore-Higgs; Bruce D Greene; Tod W Speer; Nicholas J Cassisi; Rodney R Million Journal: Cancer Date: 2002-06-01 Impact factor: 6.860
Authors: Hilliary White; Samuel Ford; Benjamin Bush; F Christopher Holsinger; Eric Moore; Tamer Ghanem; William Carroll; Eben Rosenthal; Larissa Sweeny; J Scott Magnuson Journal: JAMA Otolaryngol Head Neck Surg Date: 2013-08-01 Impact factor: 6.223
Authors: Andrew J Holcomb; Matthew Herberg; Madeleine Strohl; Edgar Ochoa; Allen L Feng; Nicholas B Abt; Tara E Mokhtari; Krish Suresh; Christopher I McHugh; Anuraag S Parikh; Peter Sadow; William Faquin; Daniel Faden; Daniel G Deschler; Mark A Varvares; Derrick T Lin; Carole Fakhry; William R Ryan; Jeremy D Richmon Journal: Head Neck Date: 2021-04-15 Impact factor: 3.821
Authors: Giuseppe Meccariello; Andrea Catalano; Giovanni Cammaroto; Giannicola Iannella; Claudio Vicini; Sheng-Po Hao; Andrea De Vito Journal: Medicina (Kaunas) Date: 2022-08-04 Impact factor: 2.948